论文部分内容阅读
目的:研究莫西沙星序贯治疗老年社区获得性肺炎的的临床疗效、安全性。方法:184例轻中度老年社区获得性肺炎患者随机分为3组。A组(对照组)仅予莫西沙星静脉滴注治疗;B组予莫西沙星序贯治疗;C组予头孢呋辛+阿奇霉素常规序贯治疗。结果:①A组、B组和C组痊愈率分别为67.2%(41/61)、65.5%(38/58)和44.7%(31/65),临床有效率分别为93.4%(57/61)、87.9%(51/58)和72.3%(47/65),细菌清除率分别为88.5%(23/26)、85.2%(23/27)和60.0%(15/25);这3个指标中,A、B两组间差异均无统计学意义,B、C两组间差异均有统计学意义;②B组和C组序贯转换时间窗分别为(2.2±1.1)天、(3.1±1.2)天,两组间差异有统计学意义:③A、B、C组不良反应发生率分别为4.9%(3/61)、3.4%(2/58)和13.8%(9/65),A、B两组间差异均无统计学意义,B、C两组间差异均有统计学意义。结论:莫西沙星序贯治疗老年社区获得性肺炎效果确切、安全。
Objective: To study the clinical efficacy and safety of moxifloxacin sequential treatment of elderly community-acquired pneumonia. Methods: 184 patients with mild to moderate senile community-acquired pneumonia were randomly divided into 3 groups. Group A (control group) received moxifloxacin intravenously only; group B received sequential moxifloxacin treatment; group C received conventional sequential treatment with cefuroxime and azithromycin. Results: The cure rates of group A, group B and group C were 67.2% (41/61), 65.5% (38/58) and 44.7% (31/65), respectively. The clinical effective rates were 93.4% (57/61) , 87.9% (51/58) and 72.3% (47/65) respectively. The bacterial clearance rates were 88.5% (23/26), 85.2% (23/27) and 60.0% (15/25) There was no significant difference between A and B groups, and the differences between B and C groups were statistically significant. The sequential window time of B and C groups was (2.2 ± 1.1) days and (3.1 ± 1.2) days, the difference between the two groups was statistically significant: ③ The incidence of adverse reactions in groups A, B and C were 4.9% (3/61), 3.4% (2/58) and 13.8% (9/65), respectively , B difference between the two groups was not statistically significant, B, C between the two groups were statistically significant. Conclusion: Moxifloxacin sequential treatment of elderly community-acquired pneumonia is effective and safe.